Detalhe da pesquisa
1.
Six-Year Survival Outcomes for Patients with HER2-Positive Early Breast Cancer Treated with CT-P6 or Reference Trastuzumab: Observational Follow-Up Study of a Phase 3 Randomised Controlled Trial.
BioDrugs;
37(3): 433-440, 2023 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-36881323
2.
Long-term efficacy and safety of CT-P6 versus trastuzumab in patients with HER2-positive early breast cancer: final results from a randomized phase III trial.
Breast Cancer Res Treat;
188(3): 631-640, 2021 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-34148205